Oxford Brain Diagnostics Ltd

Company profile

About Oxford Brain Diagnostics Ltd

Oxford Brain Diagnostics is a medical imaging company on a mission to change the way the world thinks about brain health. The company has developed proprietary technology that analyzes the cellular microstructure of the cerebral cortex in ways previously inaccessible through standard MRI scanning. Their flagship CDM® (Cortical Disarray Measurement) technology uses advanced diffusion tensor imaging to detect microscopic changes in brain tissue years before traditional symptoms appear or standard MRI scans show abnormalities. The company serves two primary markets: pharmaceutical and biotech companies conducting clinical trials for neurodegenerative diseases, and clinicians diagnosing and monitoring patients with conditions like Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. Their CDM Insights product, which has received FDA 510(k) clearance and FDA Breakthrough Device Designation, integrates with existing PACS systems to process standard anatomical and diffusion MRI data in a secure cloud environment, delivering comprehensive reports within 12 hours. Oxford Brain Diagnostics' technology enables earlier detection, more accurate differential diagnosis, and precise tracking of disease progression. For pharmaceutical companies, this translates to more targeted and efficient clinical trials with novel biomarkers that can demonstrate drug efficacy. For clinicians, it provides quantitative analysis of brain structures, microstructural changes, cortical thickness, and regional volumes in a single comprehensive report. The company is ISO 13485 and ISO 27001 certified and compliant with GDPR and HIPAA data privacy standards.

Company description · Oxford Brain Diagnostics Ltd official website